JP2023113636A5 - - Google Patents
Info
- Publication number
- JP2023113636A5 JP2023113636A5 JP2023077286A JP2023077286A JP2023113636A5 JP 2023113636 A5 JP2023113636 A5 JP 2023113636A5 JP 2023077286 A JP2023077286 A JP 2023077286A JP 2023077286 A JP2023077286 A JP 2023077286A JP 2023113636 A5 JP2023113636 A5 JP 2023113636A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody polypeptide
- polypeptide
- single variable
- variable domain
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511245P | 2017-05-25 | 2017-05-25 | |
| US62/511,245 | 2017-05-25 | ||
| JP2019564951A JP2020521458A (ja) | 2017-05-25 | 2018-05-24 | 改変IgG1 Fcドメインおよび該ドメインと抗CD40ドメイン抗体の融合物 |
| PCT/US2018/034330 WO2018217988A1 (en) | 2017-05-25 | 2018-05-24 | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564951A Division JP2020521458A (ja) | 2017-05-25 | 2018-05-24 | 改変IgG1 Fcドメインおよび該ドメインと抗CD40ドメイン抗体の融合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023113636A JP2023113636A (ja) | 2023-08-16 |
| JP2023113636A5 true JP2023113636A5 (cg-RX-API-DMAC10.html) | 2025-11-28 |
Family
ID=62599725
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564951A Pending JP2020521458A (ja) | 2017-05-25 | 2018-05-24 | 改変IgG1 Fcドメインおよび該ドメインと抗CD40ドメイン抗体の融合物 |
| JP2023077286A Pending JP2023113636A (ja) | 2017-05-25 | 2023-05-09 | 改変IgG1 Fcドメインおよび該ドメインと抗CD40ドメイン抗体の融合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564951A Pending JP2020521458A (ja) | 2017-05-25 | 2018-05-24 | 改変IgG1 Fcドメインおよび該ドメインと抗CD40ドメイン抗体の融合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20200148779A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3630832A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2020521458A (cg-RX-API-DMAC10.html) |
| KR (2) | KR102847736B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN110637035A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018217988A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6805142B2 (ja) | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Cd73に対する抗体およびその使用 |
| WO2017214452A1 (en) | 2016-06-08 | 2017-12-14 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
| US11220550B2 (en) | 2017-05-25 | 2022-01-11 | Bristol-Myers Squibb Company | Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity |
| CR20250022A (es) | 2018-04-02 | 2025-02-25 | Bristol Myers Squibb Co | Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450) |
| AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| JP7762645B2 (ja) * | 2019-08-22 | 2025-10-30 | シダラ セラピューティクス インコーポレーテッド | バリアントfcドメイン及びその使用 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| US20230140384A1 (en) * | 2020-03-09 | 2023-05-04 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
| CN115443147A (zh) * | 2020-04-23 | 2022-12-06 | 伊莱利利公司 | 抗体的皮下吸收和生物利用度 |
| CN115867580A (zh) | 2020-05-18 | 2023-03-28 | 百时美施贵宝公司 | 具有改进的药代动力学特性的抗体变体 |
| CN112552389B (zh) * | 2020-08-07 | 2023-06-06 | 中爱瑞祥(杭州)生物科技有限公司 | 一种活性肽融合蛋白及其制备方法 |
| BR112023008317A2 (pt) * | 2020-11-02 | 2024-02-06 | Attralus Inc | Proteínas de fusão sap fc e métodos de uso |
| US11912781B2 (en) | 2021-01-13 | 2024-02-27 | Visterra, Inc. | Humanized complement 5A receptor 1 antibodies and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US9051373B2 (en) * | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| EP3342782B1 (en) * | 2004-07-15 | 2022-08-17 | Xencor, Inc. | Optimized fc variants |
| AU2006304387A1 (en) * | 2005-10-14 | 2007-04-26 | Medimmune, Llc | Cell display of antibody libraries |
| WO2007113285A2 (en) * | 2006-03-31 | 2007-10-11 | Biotherapix Molecular Medicines S.L.U. | Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors |
| CA2669412A1 (en) * | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| CA2682605A1 (en) * | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| US10053513B2 (en) * | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| NO2699601T3 (cg-RX-API-DMAC10.html) | 2011-04-21 | 2018-06-16 | ||
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| WO2015134988A1 (en) * | 2014-03-07 | 2015-09-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| US20170233485A1 (en) * | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| ES2826566T3 (es) * | 2014-11-21 | 2021-05-18 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas |
| JP6805142B2 (ja) * | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Cd73に対する抗体およびその使用 |
| AU2016271111B2 (en) * | 2015-05-29 | 2022-04-28 | Bristol-Myers Squibb Company | Antibodies against OX40 and uses thereof |
| PE20181367A1 (es) * | 2015-09-30 | 2018-08-27 | Janssen Biotech Inc | Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso |
| US11220550B2 (en) * | 2017-05-25 | 2022-01-11 | Bristol-Myers Squibb Company | Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity |
-
2018
- 2018-05-24 US US16/495,994 patent/US20200148779A1/en not_active Abandoned
- 2018-05-24 WO PCT/US2018/034330 patent/WO2018217988A1/en not_active Ceased
- 2018-05-24 JP JP2019564951A patent/JP2020521458A/ja active Pending
- 2018-05-24 EP EP18731284.8A patent/EP3630832A1/en active Pending
- 2018-05-24 KR KR1020247019564A patent/KR102847736B1/ko active Active
- 2018-05-24 CN CN201880032964.0A patent/CN110637035A/zh active Pending
- 2018-05-24 KR KR1020197037759A patent/KR20200012907A/ko not_active Ceased
-
2023
- 2023-05-09 JP JP2023077286A patent/JP2023113636A/ja active Pending
-
2025
- 2025-08-28 US US19/313,261 patent/US20260042858A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| US10442857B2 (en) | Anti-IL-17 antibodies | |
| ES2569217T3 (es) | Agente para tratar enfermedades | |
| JP2020184996A5 (cg-RX-API-DMAC10.html) | ||
| US7179465B2 (en) | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type 1 interferon | |
| JP2022507741A5 (cg-RX-API-DMAC10.html) | ||
| JP2020521458A5 (cg-RX-API-DMAC10.html) | ||
| JP2020193210A5 (cg-RX-API-DMAC10.html) | ||
| KR101256400B1 (ko) | 항체 | |
| JP2023120208A5 (cg-RX-API-DMAC10.html) | ||
| JP2014530611A5 (cg-RX-API-DMAC10.html) | ||
| RU2008152443A (ru) | Антитела высокой аффинности к il-6-рецептору человека | |
| JP2017099391A5 (cg-RX-API-DMAC10.html) | ||
| JP2020532285A5 (cg-RX-API-DMAC10.html) | ||
| JP7680078B2 (ja) | 抗ヒトインターフェロンα受容体1モノクローナル抗体及びその使用 | |
| JP2010500005A5 (cg-RX-API-DMAC10.html) | ||
| KR20140108520A (ko) | CD1d에 대한 항체 | |
| CN112105373A (zh) | 治疗b型肝炎病毒感染的方法 | |
| TW202320782A (zh) | 癌症治療組合 | |
| JP2025530888A5 (cg-RX-API-DMAC10.html) | ||
| WO2023185957A1 (zh) | 抗体、融合蛋白及其用途 | |
| AU2017313632B2 (en) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 | |
| JP2017536821A5 (cg-RX-API-DMAC10.html) | ||
| EP4028056A1 (en) | Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies | |
| AU7782894A (en) | Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon |